These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11094920)

  • 41. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
    Chou R; Peterson K; Helfand M
    J Pain Symptom Manage; 2004 Aug; 28(2):140-75. PubMed ID: 15276195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke].
    Gekht AB; Burd GS; Selikhova MV; Iaish F; Beliakov VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(10):22-9. PubMed ID: 9819884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
    Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
    Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Muscle relaxants--the current position in the treatment of spasticity in orthopedics.
    Zygmunt M; Sapa J
    Ortop Traumatol Rehabil; 2015; 17(4):423-30. PubMed ID: 26468180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tizanidine: neuropharmacology and mechanism of action.
    Coward DM
    Neurology; 1994 Nov; 44(11 Suppl 9):S6-10; discussion S10-1. PubMed ID: 7970012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tizanidine in the treatment of spasticity.
    Newman PM; Nogues M; Newman PK; Weightman D; Hudgson P
    Eur J Clin Pharmacol; 1982; 23(1):31-5. PubMed ID: 6751834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Tizanidine withdrawal symptoms in stress cardiomyopathy].
    Mörkl S; Bengesser SA; Schöggl H; Bayer D; Kapfhammer HP
    Fortschr Neurol Psychiatr; 2015 Mar; 83(3):170-3. PubMed ID: 25794323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimization of Microemulgel for Tizanidine Hydrochloride.
    Jagdale S; Brahmane S; Chabukswar A
    Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):158-179. PubMed ID: 30854978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spasticity: current and future management. Royal College of Physicians, November 13, 1997.
    Hosp Med; 1998 Jan; 59(1):61-9. PubMed ID: 9798568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug treatments for spasticity.
    Yelnik AP; Simon O; Bensmail D; Chaleat-Valayer E; Decq P; Dehail P; Quentin V; Marque P; Parratte B; Pellas F; Rousseaux M; Trocello JM; Uzzan M; Dumarcet N;
    Ann Phys Rehabil Med; 2009 Dec; 52(10):746-56. PubMed ID: 19892619
    [No Abstract]   [Full Text] [Related]  

  • 52. Patient education and self-care for the management of jaw pain upon awakening: a randomized controlled clinical trial comparing the effectiveness of adding pharmacologic treatment with cyclobenzaprine or tizanidine.
    Alencar FG; Viana PG; Zamperini C; Becker A
    J Oral Facial Pain Headache; 2014; 28(2):119-27. PubMed ID: 24822235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tizanidine and tizanidine hydrochloride: on the correct tautomeric form of tizanidine.
    Bekö SL; Thoms SD; Schmidt MU; Bolte M
    Acta Crystallogr C; 2012 Jan; 68(Pt 1):o28-32. PubMed ID: 22223284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
    Johnson TR; Tobias JD
    J Child Neurol; 2000 Dec; 15(12):818-9. PubMed ID: 11198499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing spasticity with drugs.
    Simon O; Yelnik AP
    Eur J Phys Rehabil Med; 2010 Sep; 46(3):401-10. PubMed ID: 20927006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Orally administered drugs in the treatment of spasticity].
    Campistol J
    Rev Neurol; 2003 Jul 1-15; 37(1):70-4. PubMed ID: 12861514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of spasticity with tizanidine in multiple sclerosis.
    Lapierre Y; Bouchard S; Tansey C; Gendron D; Barkas WJ; Francis GS
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):513-7. PubMed ID: 3676923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of tizanidine action on spasticity.
    Milanov I; Georgiev D
    Acta Neurol Scand; 1994 Apr; 89(4):274-9. PubMed ID: 8042446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effectiveness of continuous infusion of tizanidine (Ternelin) via a feeding tube for patients with the mixed type of tetraplegia].
    Hiejima I; Kumada T; Nozaki F; Hayasi A; Miyajima T; Fujii T
    No To Hattatsu; 2015 Jan; 47(1):28-31. PubMed ID: 25803908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Study of a new myorelaxant in neurological affections (author's transl)].
    Chantraine A; Van Ouwenaller C
    J Belge Med Phys Rehabil; 1981; 4(1):5-14. PubMed ID: 7309686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.